Background
Methods
Tissue samples
Total RNA extraction Quantitative real-time polymerase chain reaction
Plasmid generation
Cell culture
Cell transfection
Cell cycle and apoptosis analysis
MTT assay and clone formation
Tumor formation assay in a nude mouse model
Western blotting analysis and antibodies
Subcellular fractionation location
Chromatin immunoprecipitation (ChIP)
RNA immunoprecipitation(RIP)
RNA pulldown assay
Bioinformatics methods
Statistical analysis
Results
FEZF1-AS1 expression levels in human gastric cancer tissue
FEZF1-AS1 upregulation associated with tumor size, stage and poor survival of gastric cancer patients
Characteristics | N (%) |
FEZF1-AS1
a
|
p-value | |
---|---|---|---|---|
High | Low | |||
Gender | 0.528 | |||
Male | 51(62.20%) | 31 | 20 | |
Female | 31(37.80%) | 21 | 10 | |
Age | 0.670 | |||
≤65 | 27(32.93%) | 18 | 9 | |
>65 | 55(67.07%) | 34 | 21 | |
Stage | 0.023* | |||
I | 9(10.97%) | 5 | 4 | |
II | 23(28.05%) | 10 | 13 | |
III | 50(60.98%) | 37 | 13 | |
Tumor size | 0.010* | |||
≤5 | 29(35.37%) | 13 | 16 | |
>5 | 53(64.63%) | 39 | 14 | |
Defferation | 0.482 | |||
Well | 37(45.12%) | 25 | 12 | |
Poorly | 45(54.88%) | 27 | 18 | |
Lauren type | ||||
Intestinal | 35(42.68%) | 20 | 15 | 0.312 |
Diffuse | 47(57.32%) | 32 | 15 |
ModelID | Score | Relativescore | Start | End | predictedsitesequence |
---|---|---|---|---|---|
MA0079.3 | 11.569 | 0.926691945898605 | 751 | 761 | GCTCCTCCCTT |
MA0079.3 | 11.472 | 0.925471574849174 | 1809 | 1819 | TTCCCTCCCTC |
MA0079.3 | 11.472 | 0.925471574849174 | 1881 | 1891 | TTCCCTCCCTC |
MA0079.3 | 11.472 | 0.925471574849174 | 1913 | 1923 | TTCCCTCCCTC |
MA0079.3 | 11.445 | 0.925131883938508 | 1905 | 1915 | CTCCCTCCCTC |
MA0079.3 | 11.445 | 0.925131883938508 | 1909 | 1919 | CTCCCTCCCTC |
MA0079.3 | 9.880 | 0.905442392264696 | 1798 | 1808 | GCTCCTCCTTT |
MA0079.3 | 9.783 | 0.904222021215265 | 1893 | 1903 | TTCCCTCCTTC |
MA0079.3 | 9.756 | 0.903882330304599 | 1877 | 1887 | CTCCCTCCTTC |
MA0079.3 | 9.756 | 0.903882330304599 | 1901 | 1911 | CTCCCTCCTTC |